$SNDX
Syndax Pharmaceuticals Inc

2022 Q1 Form 10-Q Financial Statement

#000156459022018873 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $379.0K
YoY Change -100.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.836M $5.670M
YoY Change 20.56% -4.22%
% of Gross Profit
Research & Development $30.02M $21.87M
YoY Change 37.27% 128.72%
% of Gross Profit
Depreciation & Amortization $11.00K $20.00K
YoY Change -45.0% 0.0%
% of Gross Profit
Operating Expenses $30.02M $27.54M
YoY Change 9.0% 77.93%
Operating Profit -$36.86M -$27.16M
YoY Change 35.69% 79.89%
Interest Expense $651.0K $623.0K
YoY Change 4.49% 38.75%
% of Operating Profit
Other Income/Expense, Net $116.0K -$60.00K
YoY Change -293.33% -55.88%
Pretax Income -$37.17M -$27.72M
YoY Change 34.09% 81.89%
Income Tax
% Of Pretax Income
Net Earnings -$37.17M -$27.72M
YoY Change 34.07% 81.96%
Net Earnings / Revenue -7314.78%
Basic Earnings Per Share -$0.63
Diluted Earnings Per Share -$630.2K -$538.3K
COMMON SHARES
Basic Shares Outstanding 58.98M
Diluted Shares Outstanding 58.98M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $410.9M $276.2M
YoY Change 48.77% 172.66%
Cash & Equivalents $188.8M $64.40M
Short-Term Investments $222.1M $211.8M
Other Short-Term Assets $8.989M $2.500M
YoY Change 259.56% -3.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $420.1M $278.9M
YoY Change 50.61% 167.64%
LONG-TERM ASSETS
Property, Plant & Equipment $1.139M $600.0K
YoY Change 89.83% 131.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.027M $100.0K
YoY Change 927.0% 0.0%
Total Long-Term Assets $2.166M $800.0K
YoY Change 170.75% -19.52%
TOTAL ASSETS
Total Short-Term Assets $420.1M $278.9M
Total Long-Term Assets $2.166M $800.0K
Total Assets $422.2M $279.7M
YoY Change 50.96% 165.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.231M $6.500M
YoY Change 26.63% -27.78%
Accrued Expenses $18.75M $11.90M
YoY Change 57.58% 43.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.568M $4.600M
YoY Change -22.43%
Total Short-Term Liabilities $30.55M $24.60M
YoY Change 24.19% 30.85%
LONG-TERM LIABILITIES
Long-Term Debt $16.48M $15.60M
YoY Change 5.63% -21.21%
Other Long-Term Liabilities $643.0K $11.30M
YoY Change -94.31% -13.74%
Total Long-Term Liabilities $17.12M $26.90M
YoY Change -36.35% -18.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.55M $24.60M
Total Long-Term Liabilities $17.12M $26.90M
Total Liabilities $47.67M $51.50M
YoY Change -7.43% -0.19%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $374.5M $228.2M
YoY Change
Total Liabilities & Shareholders Equity $422.2M $279.7M
YoY Change 50.96% 165.87%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$37.17M -$27.72M
YoY Change 34.07% 81.96%
Depreciation, Depletion And Amortization $11.00K $20.00K
YoY Change -45.0% 0.0%
Cash From Operating Activities -$41.93M -$22.59M
YoY Change 85.63% 41.85%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $8.182M -$29.23M
YoY Change -127.99% 53.44%
Cash From Investing Activities $8.182M -$29.23M
YoY Change -127.99% 53.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 557.0K 960.0K
YoY Change -41.98% -98.25%
NET CHANGE
Cash From Operating Activities -41.93M -22.59M
Cash From Investing Activities 8.182M -29.23M
Cash From Financing Activities 557.0K 960.0K
Net Change In Cash -33.19M -50.86M
YoY Change -34.73% -354.03%
FREE CASH FLOW
Cash From Operating Activities -$41.93M -$22.59M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-11
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37708
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0162505
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
35 Gatehouse Drive
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building D
CY2022Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Floor 3
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
115000
CY2022Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
12979000
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6894000
CY2022Q1 us-gaap Loans Payable Current
LoansPayableCurrent
3568000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
187000
CY2022Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
16479000
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2022Q1 dei City Area Code
CityAreaCode
781
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
419-1400
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188773000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30022000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36858000
CY2022Q1 us-gaap Interest Expense
InterestExpense
651000
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-113000
CY2022Q1 sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
110000
CY2021Q1 sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
101000
CY2022Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
152000
CY2021Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
114000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
187000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3478000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3856000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41931000
CY2022Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
42266000
CY2021Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
66728000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
50448000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
37500000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8182000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29228000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
92000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
465000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
557000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33192000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222080000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
470000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Syndax Pharmaceuticals, Inc. (“we,” “us,” “our” or the “Company”) is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. We were incorporated in Delaware in 2005. We base our operations in Waltham, Massachusetts and we operate in one segment.</p>
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51499831
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6900000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates<span style="font-weight:bold;"> </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates and assumptions about future events and their effects cannot be determined with certainty and therefore require the exercise of judgement. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities.  These estimates may change as new events occur and additional information is obtained and are recognized in the consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company’s financial statements. </p>
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37169000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-27723000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37169000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27723000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58978615
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3036719
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
8.00
CY2021Q1 sndx Number Of Pre Funded Warrants Exchanged For Common Stock
NumberOfPreFundedWarrantsExchangedForCommonStock
250000
CY2021Q4 sndx Number Of Pre Funded Warrants Cashless Exchanged For Common Stock
NumberOfPreFundedWarrantsCashlessExchangedForCommonStock
475784
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
187000
CY2022Q1 sndx Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue
187000
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q1 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
209797000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
640000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
209157000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
343074000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
70000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
343119000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9032000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1451000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
2154000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
642000
CY2022Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
158000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
429000
CY2022Q1 sndx Reimbursable Costs
ReimbursableCosts
6260000
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
460000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
380000
CY2022Q1 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
8320000
CY2021Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
7760000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1937000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4342000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
520000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
662000
CY2022Q1 sndx Accrued Research And Development Costs Other
AccruedResearchAndDevelopmentCostsOther
5750000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1893000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1702000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18421000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14466000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3478000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2767000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3478000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2767000
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
28839
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
465000
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100954
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
881000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
14765000
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5235000
CY2022Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2022Q1 sndx Amortized Losses Reacquired Debt Noncurrent
AmortizedLossesReacquiredDebtNoncurrent
162000
CY2022Q1 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
115000
CY2022Q1 us-gaap Loans Payable
LoansPayable
20047000
CY2022Q1 us-gaap Loans Payable Current
LoansPayableCurrent
3568000
CY2022Q1 us-gaap Long Term Loans Payable
LongTermLoansPayable
16479000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
408368000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3478000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-685000
CY2022Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
92000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-37169000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
374549000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228205000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
252188000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2767000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
79000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
881000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-27723000

Files In Submission

Name View Source Status
0001564590-22-018873-index-headers.html Edgar Link pending
0001564590-22-018873-index.html Edgar Link pending
0001564590-22-018873.txt Edgar Link pending
0001564590-22-018873-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-10q_20220331.htm Edgar Link pending
sndx-10q_20220331_htm.xml Edgar Link completed
sndx-20220331.xsd Edgar Link pending
sndx-20220331_cal.xml Edgar Link unprocessable
sndx-20220331_def.xml Edgar Link unprocessable
sndx-20220331_lab.xml Edgar Link unprocessable
sndx-20220331_pre.xml Edgar Link unprocessable
sndx-ex101_11.htm Edgar Link pending
sndx-ex102_12.htm Edgar Link pending
sndx-ex311_7.htm Edgar Link pending
sndx-ex312_8.htm Edgar Link pending
sndx-ex321_6.htm Edgar Link pending